Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | PHASE3 | RECRUITING | 700 | — | — | Mar 5, 2026 | Sep 28, 2029 | Jun 1, 2026 | 274 | United States, Argentina +19 |
Defined as the time from the date of randomization to the date of the first documented progression as determined by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 or death due to any cause.
| Arm | Type | Description |
|---|---|---|
| INCA33890 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose. |
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose. |
| Name | Type | Description |
|---|---|---|
| INCA33890 | DRUG | INCA33890 will be administered at protocol defined dose. |
| Placebo | DRUG | Placebo will be administered at protocol defined dose. |
| Bevacizumab | DRUG | Bevacizumab will be administered at protocol defined dose. |
| FOLFOX | DRUG | FOLFOX will be administered at protocol defined dose. |
Inclusion Criteria: * Stage IV colorectal adenocarcinoma not amenable to curative resection. * No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment...